

Ref. No: 1190
Date: 10/09/24
Subject: Biologic medicines in dermatology

REQUEST

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab
- Ustekinumab Biosimilar
- Omalizumab

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Bimekizumab
- Certolizumab
- Infliximab - Remicade
- Infliximab Biosimilar

- Secukinumab
- Ustekinumab
- Ustekinumab Biosimilar

RESPONSE

Southport and Ormskirk response

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira - 4
- Adalimumab Biosimilar - 47
- Apremilast - 0
- Bimekizumab - 0
- Brodalumab - 0
- Certolizumab - 0
- Deucravacitinib - 0
- Dimethyl fumarate - 0
- Etanercept – Enbrel - 0
- Etanercept Biosimilar - 1
- Guselkumab - 5
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 0
- Ixekizumab - 12
- Risankizumab - 29
- Secukinumab - 10
- Tildrakizumab - 0
- Ustekinumab - 5
- Ustekinumab Biosimilar
- Omalizumab - 1

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

- Adalimumab – Humira - 0
- Adalimumab Biosimilar - 0
- Bimekizumab - 0
- Certolizumab - 0
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 0
- Secukinumab - 0
- Ustekinumab - 0
- Ustekinumab Biosimilar - 0

St. Helens and Knowsley response

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira - 7
- Adalimumab Biosimilar - 60
- Apremilast - 63
- Bimekizumab - 0
- Brodalumab - 0
- Certolizumab - 1
- Deucravacitinib - 0
- Dimethyl fumarate - 7
- Etanercept – Enbrel - 0
- Etanercept Biosimilar - 1
- Guselkumab - 22
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 0
- Ixekizumab - 4
- Risankizumab - 3
- Secukinumab - 7
- Tildrakizumab - 0
- Ustekinumab - 20
- Ustekinumab Biosimilar - 0
- Omalizumab - 1

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

Unable to answer as we do not have information on specific indications.